fulvestrant has been researched along with Breast Cancer, Male in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Arnedos, M; Arteaga, CL; Baselga, J; Bidard, FC; Boni, V; Brufksy, AM; Bryce, R; Cai, Y; Cervantes, A; Chandarlapaty, S; de la Fuente, MI; Dujka, M; Eli, LD; Gavrila, EI; Gonzàlez-Farré, X; Gorelick, AN; Hyman, DM; Jhaveri, K; Juric, D; Lalani, AS; Lanman, RB; Loi, S; Lu, J; Mann, G; Mau-Sørensen, M; Mayer, IA; Melcer, M; Meric-Bernstam, F; Moreno, V; Nagy, RJ; Piha-Paul, SA; Samoila, A; Saura, C; Scaltriti, M; Schram, AM; Schwartzberg, LS; Selcuklu, SD; Shapiro, GI; Smyth, LM; Sohn, J; Solit, DB; Spanggaard, I; Taylor, BS; Ulaner, GA; Won, HH; Xu, F; Zimel, C | 1 |
| Corbaux, P; Sabatier, R | 1 |
| Arnaud, A; Debourdeau, P; Grenier, J; Vazquez, L | 1 |
| Dalmau, E; Fernández-Morales, LA; Marín, M; Martinez Vila, C; Oliveres, H; Pardo, JC; Ribera, P; Segui, MA | 1 |
| Chrysikos, D; Dimopoulos, MA; Psaltopoulou, T; Sergentanis, TN; Zagouri, F | 1 |
| Eguchi, S; Esaki, T; Ishida, M; Kuba, S; Nakamura, Y; Ohno, S; Oikawa, M; Taguchi, K; Tokunaga, E; Yamanouchi, K | 1 |
| Currin, ER; Krohn, KA; Kurland, BF; Lee, JH; Linden, HM; Link, JM; Mankoff, DA; Peterson, LM; Schubert, EK | 1 |
| Aranda, E; Berciano Guerrero, M; de la Haba Rodríguez, JR; Porras Quintela, I; Pulido Cortijo, G | 1 |
| Gandini, C; Lutman, FR; Masci, G; Pedrazzoli, P; Santoro, A; Torrisi, R; Zuradelli, M | 1 |
| Beyer, A; Cai, WY; Elledge, R; Fuqua, S; Hilsenbeck, S; Huang, J; Massarweh, S; Rimawi, M; Sexton, K; Tham, YL; Tsimelzon, A; Weiss, H | 1 |
| Bartsch, R; Chrysikos, D; Rudas, M; Sergentanis, TN; Steger, G; Zagouri, F; Zografos, E; Zografos, G | 1 |
| Agrawal, A; Cheung, KL; Robertson, JF | 1 |
| Eucker, J; Kühnl, A; Possinger, K | 1 |
3 review(s) available for fulvestrant and Breast Cancer, Male
| Article | Year |
|---|---|
[Patients treated with palbociclib and endocrine therapy for metastatic breast cancer: Can we predict the occurrence of severe early hematological toxicity?]
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Breast Neoplasms, Male; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Male; Middle Aged; Multivariate Analysis; Neutropenia; Piperazines; Progression-Free Survival; Pyridines; Retrospective Studies; Thrombocytopenia | 2021 |
Fulvestrant and male breast cancer: a pooled analysis.
Topics: Adult; Aged; Breast Neoplasms, Male; Disease-Free Survival; Estradiol; Estrogen Antagonists; Fulvestrant; Hormones; Humans; Male; Middle Aged; Tamoxifen | 2015 |
Aromatase inhibitors with or without luteinizing hormone-releasing hormone agonist for metastatic male breast cancer: report of four cases and review of the literature.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms, Male; Estradiol; Fulvestrant; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged | 2016 |
2 trial(s) available for fulvestrant and Breast Cancer, Male
| Article | Year |
|---|---|
Efficacy and Determinants of Response to HER Kinase Inhibition in
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Treatment Outcome | 2020 |
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cell Cycle; Cyclin D1; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Ki-67 Antigen; Male; Mitogen-Activated Protein Kinases; Neoadjuvant Therapy; Nitriles; Oncogene Protein v-akt; Proto-Oncogene Proteins; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2011 |
8 other study(ies) available for fulvestrant and Breast Cancer, Male
| Article | Year |
|---|---|
[New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; Estrogens; Female; Fulvestrant; Humans; Male; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Progesterone; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Thiazoles | 2020 |
Fulvestrant plus LHRH analogues in male with synchronous breast and prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Estradiol; Fulvestrant; Gonadotropin-Releasing Hormone; Humans; Letrozole; Male; Neoplasms, Multiple Primary; Nitriles; Prostatic Neoplasms; Tamoxifen; Triazoles | 2017 |
Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Breast Neoplasms, Male; Disease-Free Survival; Estradiol; Estrogen Receptor alpha; Female; Fluorodeoxyglucose F18; Fulvestrant; Humans; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2 | 2017 |
Fulvestrant in advanced male breast cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Combined Modality Therapy; Estradiol; Fulvestrant; Humans; Lung Neoplasms; Male; Mastectomy, Radical; Radiotherapy | 2009 |
Fulvestrant for advanced male breast cancer patients: a case series.
Topics: Breast Neoplasms, Male; Estradiol; Fulvestrant; Humans; Male; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Testosterone | 2011 |
Fulvestrant and male breast cancer: a case series.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms, Male; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Male; Middle Aged | 2013 |
Fulvestrant in advanced male breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms, Male; Estradiol; Fulvestrant; Humans; Injections, Intramuscular; Male; Middle Aged | 2007 |
[Systemic therapy of male breast cancer].
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms, Male; Combined Modality Therapy; Cyclophosphamide; Estradiol; Fluorouracil; Fulvestrant; Humans; Male; Methotrexate; Orchiectomy; Randomized Controlled Trials as Topic; Survival Rate; Tamoxifen; Treatment Outcome | 2007 |